Alvarez-Ossorio MJ, et al. - The changes in estimated glomerular filtration rate (eGFR) were assessed in association with treatment with direct-acting antivirals (DAAs) against hepatitis C virus infection currently used in Spain and Portugal. With all-oral DAAs, a slight decline in eGFR was apparent during therapy. Furthermore, in subjects with normal to moderately impaired renal function, persistence of this impact for up to 12 weeks following treatment cessation, was noted regardless of HIV status. Concomitant use of tenofovir + a ritonavir-boosted HIV protease inhibitor (PI/r) did not seem to have an influence on eGFR.

• Researchers selected patients treated with DAAs for at least 12 weeks and with eGFR ≥30 ml/min/1.73 m² at baseline, from an international, prospective multicohort study.
• They used the CKD-EPI formula to determine eGFR.

• This study included a total of 1131 patients; 658 (58%) were HIV/HCV-coinfected patients.
• Researchers found that among the 901 patients treated for 12 weeks, median (interquartile range) eGFR was 100 (87-107) at baseline vs 97 (85-105) ml/min/1.73 m² at week 12 of follow-up (FU12) post-treatment (p<0.001).
• They also noted that baseline vs FU12 eGFR were 104 (86-109) vs 104 (91-110) ml/min/1.73 m² (p=0.913) in HIV-coinfected subjects who received tenofovir + a ritonavir-boosted HIV protease inhibitor (PI/r).
• Data revealed no significant changes in the eGFR among subjects receiving ombitasvir/paritaprevir with or without dasabuvir.
• In addition, findings demonstrated that, of 1100 subjects with eGFR >60 ml/min/1.73 m² at baseline, 22 (2%) had eGFR <60 ml/min/1.73 m² at FU12, but none presented with eGFR <30 ml/min/1.73 m².